<DOC>
	<DOCNO>NCT02530515</DOCNO>
	<brief_summary>Patient 's immune system often damage chemotherapy CLL . Researchers want learn give T-cells ( immune cell ) expand specially process laboratory ( activate ) help CLL patient ' immune system recover chemotherapy . This may help low chance infection . The goal clinical research study learn activate T-cell infusion , give without lenalidomide , help restore patient ' immune system give chemotherapy ( rituximab fludarabine cyclophosphamide bendamustine ) . The safety treatment combination also study . Researchers also want learn activate T-cells may also able kill cancer cell .</brief_summary>
	<brief_title>Trial Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group . You equal chance assign either group : - If Group 1 , receive chemotherapy activate T-cell infusion . - If Group 2 , receive chemotherapy , activate T-cell infusion , 6 month lenalidomide therapy . - If doctor determines able receive chemotherapy certain genetic mutation , Group 3 . Patients Group 3 receive activate T-cell infusion . Central Venous Catheter : Many drug give study activate T-cells give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein local anesthesia . Blood sample also draw CVC . The CVC remain body treatment . Your doctor explain procedure detail , require sign separate consent form . T-Cell Collection : Blood ( 17 tablespoon ) draw collect T-cells . These cell expand activated laboratory give back chemotherapy complete . Chemotherapy T-cell Infusion : The day receive activate T-cells call minus day . The day receive activate T-cells call Day 0 . The day receive activate T-cells call plus day . On Day -5 , receive rituximab vein 4-6 hour fludarabine vein 1 hour . You receive either cyclophosphamide vein 3 hour bendamustine 1 hour . Your doctor decide whether receive cyclophosphamide bendamustine . On Day -4 -3 , receive fludarabine vein 1 hour , either cyclophosphamide vein 3 hour bendamustine 1 hour . On Days -2 -1 , rest receive nothing . On Day 0 , receive activate T-cells vein 10-30 minute . Before infusion , receive acetaminophen ( Tylenol ) mouth diphenhydramine hydrochloride ( Benadryl ) mouth vein 30-60 minute infusion . These drug use help low risk side effect . If experience side effect treatment , must stay clinic observe symptom stop completely . If severe allergic reaction infusion activate T-cells , infusion stop right away give need care doctor staff . If Group 2 , blood count high enough activate T-cell infusion , take lenalidomide mouth 1 time day time day 6 month . If able , also take aspirin another drug instruct doctor day help prevent blood clot . You may ask study staff information drug give risk . You ask complete study drug diary bring study visit . The study staff tell . If experience side effect lenalidomide , dose reduce . If continue experience side effect , doctor may decide stop lenalidomide . Study Visits ( All Groups ) : On day activate T-cell infusion : - You physical exam . - Blood ( 4 tablespoon ) draw routine test , check status disease , test immune system , test CMV , EBV , polyoma virus . At 1 , 3 , 12 month activate T-cell infusion : - You physical exam . - Blood ( 4 tablespoon ) draw routine test , check status disease , test immune system , test CMV , EBV , polyoma virus . - At 3 12 month T-cell infusion , bone marrow aspiration check status disease . At 2 6 month activate T-cell infusion , blood ( 2 tablespoon ) drawn test immune system test CMV , EBV , polyoma virus . Additional Study Visits Group 2 : Every 28 day , blood ( 2 tablespoon ) draw routine test . If become pregnant regular menstrual cycle , blood ( 2 teaspoon ) draw pregnancy test follow schedule : - Within 10-14 day , within 24 hour first dose lenalidomide , even menses due treatment disease little one menstrual period past 24 month . - One ( 1 ) time week 4 week , every 4 week take lenalidomide . - Four ( 4 ) week stop take lenalidomide . If irregular menstrual cycle , pregnancy test every week first 28 day , every 14 day take lenalidomide , take lenalidomide therapy , 14 day 28 day stop take lenalidomide . Length Study : Your active participation study 12 month follow-up visit . You may take study early unable receive T-cell infusion , intolerable side effect , unable follow study direction , doctor think best interest , study stop , choose leave study early . Your participation study follow-up period . Follow-Up : Starting year half activate T-cell infusion , study staff call ask health disease status every 6 month 5 year . The phone call take 5-15 minute time . This investigational study . Bendamustine , cyclophosphamide , fludarabine , rituximab FDA approve commercially available treatment CLL . Lenalidomide FDA approve commercially available treatment type cancer . The use lenalidomide treatment CLL investigational . The T cell process use study FDA approve commercially available . It currently use research purpose . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . All patient must diagnosis CLL immunophenotyping flow cytometry analysis blood bone marrow . 1 ) Patients must meet criterion treatment base criterion propose NCIsponsored CLL Working Group include least one following : ) weight loss 10 % precede 6 month ; , b ) extreme fatigue attributable progressive disease ; , c ) fever night sweat without evidence infection ; , ) worsen anemia ( Rai stage Ill ) thrombocytopenia ( Rai stage IV ) ; , e ) massive lymphadenopathy ( &gt; 10 cm ) rapidly progressive lymphocytosis ( lymphocyte doubling time &lt; 6 month ) ; , f ) prolymphocytic Richter 's transformation ; , 2 ) Patients CLL receive least one prior line therapy ; , 3 ) Patients CLL frequent infection and/or recurrent secondary cancer . 2 . No active CNS disease . 3 . All patient must Karnofsky Performance Score &gt; 60 % . 4 . Calculated creatinine clearance ( CockcroftGault ) &gt; 50 ml/min . 5 . Patients must untreated uncontrolled lifethreatening infection . 6 . Patients must sign informed consent . 7 . Females childbearing potential must negative serum pregnancy test minimum sensitivity 50 mIU/mL agree use two medically accept form contraception time initial screen completion study practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start lenalidomide ; 2 ) throughout entire duration lenalidomide treatment ; 3 ) dose interruption ; 4 ) least 28 day lenalidomide discontinuation . 8 . Females reproductive potential receive lenalidomide must adhere scheduled pregnancy test require Revlimid REMS ( TM ) program . 9 . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . 10 . All study participant receive lenalidomide must register mandatory Revlimid REMS ( TM ) program , willing able comply requirement REMS ( TM ) program . 11 . Patients meet eligibility protocol candidate receive chemotherapy may treat Arm C. 12 . Patients 17p deletion enrol Arm C. These patient receive expand T cell without lymphodepleting chemotherapy . 1 . Receipt glucocorticoid ( exception inhale glucocorticoid steroid use allergic rhinitis pulmonary disease ) within 2 week registration . 2 . Autoimmune disease relate CLL , e.g. , idiopathic thrombocytopenic purpura ( ITP ) autoimmune hemolytic anemia , permit require active treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>T-cells</keyword>
	<keyword>Immune cell</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
	<keyword>Bendamustine HCL</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>SDX-105</keyword>
	<keyword>Treanda</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
</DOC>